市场调查报告书
商品编码
1467906
2024-2032 年按类型、用途、最终用户和地区分類的乳房病变定位方法市场报告Breast Lesion Localization Methods Market Report by Type, Usage, End User, and Region 2024-2032 |
IMARC Group年,全球乳房病变定位方法市场规模达12.142亿美元。
乳房病变定位方法是指用于检测因疾病或损伤引起的乳房组织异常变化(也称为乳房病变)的各种程序。一些常用的方法包括线定位、碳标记、无线电导引隐匿性病变定位 (ROLL)、放射性种子定位 (RSL)、磁性种子定位 (Magseed) 和术中超音波 (IOUS)。这些技术可帮助医生和医疗保健专业人员做出明智的决定并确定患者的理想治疗或手术。随着外科、影像和生物医学技术的进步,乳房病变定位方法已经显着发展,目前正在推动医疗保健领域的需求。
由于生活方式的改变和不健康的饮食,乳癌病例显着增加是推动市场成长的主要因素。除此之外,越来越多的患者需要进行肿块切除术和手术活检,这增加了对乳房病灶定位方法的需求,以确保准确切除目标病灶。此外,各国管理机构正在采取有利倡议,以提高人们对早期发现乳癌益处的认识。例如,澳洲政府启动了BreastScreen Australia,这是一项全国性乳癌筛检计划,每两年为50-74岁的女性提供免费乳房X光检查。再加上越来越多的政府和私人对乳癌诊断、活检和其他相关医疗程序的报销政策以及领先企业推出的创新乳房病变定位设备,正在促进市场成长。此外,对研发(R&D)活动的大量投资为市场参与者提供了利润丰厚的机会。其他因素,包括接受丰胸等整容手术的人数不断增加、医疗保健基础设施改善、技术进步以及消费者医疗保健支出增加,也创造了积极的市场前景。
The global breast lesion localization methods market size reached US$ 1,214.2 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 2,656.8 Million by 2032, exhibiting a growth rate (CAGR) of 8.9% during 2024-2032.
Breast lesion localization methods refer to various procedures employed to detect abnormal changes in the breast tissue, also called a breast lesion, caused due to a disease or injury. Some commonly used methods include wire localization, carbon marking, radio-guided occult lesion localization (ROLL), radioactive seed localization (RSL), magnetic seed localization (Magseed), and intraoperative ultrasound (IOUS). These techniques assist doctors and healthcare professionals in making informed decisions and determining the ideal treatment or surgery for the patient. With advancements in surgical, imaging and biomedical technology, breast lesion localization methods have significantly evolved, which is presently driving their demand in the healthcare sector.
A significant increase in breast cancer cases due to changing lifestyles, and unhealthy diets represents the primary factor driving the market growth. Besides this, the growing number of patients requiring lumpectomy and surgical biopsy procedures is augmenting the demand for breast lesion localization methods to ensure accurate removal of the target lesion. Additionally, the governing agencies of various countries are taking favorable initiatives to spread awareness regarding the benefits of early detection of breast cancer. For instance, the Government of Australia launched BreastScreen Australia, a national breast cancer screening program that provides a free mammogram to women aged 50-74 every two years. This, in confluence with the increasing number of government and private reimbursement policies for breast cancer diagnosis, biopsy and other related medical procedures and the launch of innovative breast lesion localization devices by leading players, is catalyzing the market growth. Furthermore, heavy investments in research and development (R&D) activities are offering lucrative opportunities to the market players. Other factors, including the rising number of individuals undergoing cosmetic surgeries like breast enhancement, improving healthcare infrastructure, technological advancements, and increasing consumer healthcare spending, are also creating a positive market outlook.
IMARC Group provides an analysis of the key trends in each sub-segment of the global breast lesion localization methods market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on type, usage and end user.
Wire Localization
Radioisotope Localization
Magnetic Tracers Localization
Others
Tumor Identification
Sentinel Lymph Node Identification
Lumpectomy
Mastectomy
Hospitals
Diagnostic Centres
Oncology Clinics
Ambulatory Surgical Centers
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Argon Medical Devices Inc., Becton Dickinson and Company, Cook Group Incorporated, CP Medical Inc. (Theragenics Corporation), Endomagnetics Ltd., Hologic Inc., IsoAid LLC, IZI Medical Products (Landauer Inc), Laurane Medical LLC, Leica Biosystems Nussloch GmbH (Danaher Corporation), Merit Medical Systems Inc. and Sterylab S.r.l.